U.S. to pay $2.1 billion to Sanofi, GSK, in COVID-19 vaccine deal
By Michael Erman and Carl O'Donnell (Reuters) - The U.S. government will pay $2.1 billion to Sanofi SA and GlaxoSmithKline Plc for COVID-19 vaccines to cover 50 million people and to underwrite the drugmakers' testing and manufacturing, the companies said on Friday. The drugmakers also said they are in advanced discussions to supply up to 300 million doses of the experimental vaccine for the 27-country European Union.
By Michael Erman and Carl O'Donnell
(Reuters) - The U.S. government will pay $2.1 billion to Sanofi SA and GlaxoSmithKline Plc for COVID-19 vaccines to cover 50 million people and to underwrite the drugmakers' testing and manufacturing, the companies said on Friday.
The drugmakers also said they are in advanced discussions to supply up to 300 million doses of the experimental vaccine for the 27-country European Union.
The U.S. award is the biggest yet from 'Operation Warp Speed', the White House initiative aimed at accelerating access to vaccines and treatments to fight COVID-19, the respiratory disease caused by the novel coronavirus.
The deal, announced by the U.S. Department of Health and Human Services and Department of Defense, works out at a cost of around $42 per person inoculated.
That is almost identical to the $40 per patient the U.S. agreed to pay Pfizer Inc and BioNTech SE when it inked a nearly $2 billion deal for 50 million courses of that potential vaccine last week.
The Sanofi-GSK deal is for 100 million doses, at two per person, and gives the U.S. government an option to purchase an additional 500 million doses at an unspecified price. Sanofi and GSK plan to start clinical trials for the vaccine in September.
Sanofi executive Clement Lewin said the companies had not yet agreed with the U.S. on a specific price for the additional doses.
GSK said in a statement that more than half of the total funding will go into further development of the vaccine, including clinical trials, with the remainder used for a manufacturing ramp-up and delivery of doses.
The two companies' inoculation is combination of a vaccine based on Sanofi's flu shots and a complementary technology from GSK called an adjuvant, designed to improve the vaccine's potency.
Sanofi will receive the bulk of the proceeds from the deal.
It marks the second contract for the Franco-British pair's vaccine candidate after they agreed earlier this week to supply 60 million doses to the British government.
Reuters reported last week that Pfizer's deal was expected to set a pricing benchmark for future deals between drugmakers and governments.
Moderna Inc and Pfizer began two 30,000-subject trials of COVID-19 vaccines on Monday that could clear the way for regulatory approval and use by the end of 2020.
(Reporting by Michael Erman and Carl O'Donnell in New York; Additional reporting by Ludwig Burger in Frankfurt and Deena Beasley in Los Angeles; editing by Jan Harvey and Grant McCool)
This story has not been edited by Firstpost staff and is generated by auto-feed.
Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.
By Foo Yun Chee BRUSSELS (Reuters) - The European Union's executive on Friday wrapped up preliminary talks with French drugmaker Sanofi aimed at securing its COVID-19 vaccine for the 27-country EU bloc, the latest deal with vaccine producers. Armed with an emergency fund of more than 2 billion euros ($2.4 billion), the European Commission wants to strike deals with up to six drugmakers for their vaccines for their 450 million citizens against the coronavirus that has killed 674,000 people worldwide
By Lucia Mutikani WASHINGTON (Reuters) - U.S. consumer spending increased for a second straight month in June, setting up consumption for a rebound in the third quarter, though the recovery could be limited by a resurgence in COVID-19 cases and the end of expanded unemployment benefits.
By Steve Holland and Daphne Psaledakis WASHINGTON (Reuters) - The United States intensified its economic pressure on China's Xinjiang province on Friday, imposing sanctions on a powerful Chinese company and two officials for what it said were human rights abuses against Uighurs and other ethnic minorities. The move, the latest blow to U.S.-China relations, came a week after U.S